Hans-Joachim Anders
@hjanders.bsky.social
Physician scientist from LMU Munich trying to understand how to maximise kidney lifespan for patients with kidney diseases
Reposted by Hans-Joachim Anders
Sodium glucose cotransporter 2 inhibition does not improve active lupus nephritis in MRLlpr/lpr mice
doi.org/10.1016/j.kint.2025.09.026
#NephSky #MedSky #lupus #nupusnephritis #kidneydisease
@vhir.bsky.social @lmumuenchen.bsky.social @hjanders.bsky.social @pepasolerr.bsky.social
doi.org/10.1016/j.kint.2025.09.026
#NephSky #MedSky #lupus #nupusnephritis #kidneydisease
@vhir.bsky.social @lmumuenchen.bsky.social @hjanders.bsky.social @pepasolerr.bsky.social
October 31, 2025 at 8:40 PM
Sodium glucose cotransporter 2 inhibition does not improve active lupus nephritis in MRLlpr/lpr mice
doi.org/10.1016/j.kint.2025.09.026
#NephSky #MedSky #lupus #nupusnephritis #kidneydisease
@vhir.bsky.social @lmumuenchen.bsky.social @hjanders.bsky.social @pepasolerr.bsky.social
doi.org/10.1016/j.kint.2025.09.026
#NephSky #MedSky #lupus #nupusnephritis #kidneydisease
@vhir.bsky.social @lmumuenchen.bsky.social @hjanders.bsky.social @pepasolerr.bsky.social
Now open access in @ndt-era.bsky.social
Rationale, Design, and Baseline Characteristics of the TRANSCEND-CKD trial of Retatrutide in pts with CKD
🧐Retatrutide is a novel triple incretin agonist targeting GIP, GLP-1, and glucagon receptors
▶️ academic.oup.com/ndt/article/...
Rationale, Design, and Baseline Characteristics of the TRANSCEND-CKD trial of Retatrutide in pts with CKD
🧐Retatrutide is a novel triple incretin agonist targeting GIP, GLP-1, and glucagon receptors
▶️ academic.oup.com/ndt/article/...
October 30, 2025 at 8:56 AM
Now open access in @ndt-era.bsky.social
Rationale, Design, and Baseline Characteristics of the TRANSCEND-CKD trial of Retatrutide in pts with CKD
🧐Retatrutide is a novel triple incretin agonist targeting GIP, GLP-1, and glucagon receptors
▶️ academic.oup.com/ndt/article/...
Rationale, Design, and Baseline Characteristics of the TRANSCEND-CKD trial of Retatrutide in pts with CKD
🧐Retatrutide is a novel triple incretin agonist targeting GIP, GLP-1, and glucagon receptors
▶️ academic.oup.com/ndt/article/...
Now open access in @ndt-era.bsky.social
Autosomal Dominant Tubulointerstitial Kidney Disease (ADTKD) in Chinese Pts
🧐This Chinese ADTKD cohort reveals a high prevalence of UMOD and HNF1B variants
▶️ academic.oup.com/ndt/article-...
Autosomal Dominant Tubulointerstitial Kidney Disease (ADTKD) in Chinese Pts
🧐This Chinese ADTKD cohort reveals a high prevalence of UMOD and HNF1B variants
▶️ academic.oup.com/ndt/article-...
October 28, 2025 at 9:45 AM
Now open access in @ndt-era.bsky.social
Autosomal Dominant Tubulointerstitial Kidney Disease (ADTKD) in Chinese Pts
🧐This Chinese ADTKD cohort reveals a high prevalence of UMOD and HNF1B variants
▶️ academic.oup.com/ndt/article-...
Autosomal Dominant Tubulointerstitial Kidney Disease (ADTKD) in Chinese Pts
🧐This Chinese ADTKD cohort reveals a high prevalence of UMOD and HNF1B variants
▶️ academic.oup.com/ndt/article-...
Now online in @ndt-era.bsky.social
Neutrophil infiltration of kidney grafts: incidence, associated factors and graft survival
🧐NTI should prompt the search for urinary tract infection and rejection
▶️ academic.oup.com/ndt/article-...
Neutrophil infiltration of kidney grafts: incidence, associated factors and graft survival
🧐NTI should prompt the search for urinary tract infection and rejection
▶️ academic.oup.com/ndt/article-...
October 28, 2025 at 9:41 AM
Now online in @ndt-era.bsky.social
Neutrophil infiltration of kidney grafts: incidence, associated factors and graft survival
🧐NTI should prompt the search for urinary tract infection and rejection
▶️ academic.oup.com/ndt/article-...
Neutrophil infiltration of kidney grafts: incidence, associated factors and graft survival
🧐NTI should prompt the search for urinary tract infection and rejection
▶️ academic.oup.com/ndt/article-...
Reposted by Hans-Joachim Anders
Now online in @ndt-era.bsky.social
Recombinant alpha-1 microglobulin to improve outcomes in survivors of AKI
🧐RMC-035 may improve kidney outcomes in settings characterized by oxidative and ischemia-reperfusion injury.
▶️ academic.oup.com/ndt/article-...
Recombinant alpha-1 microglobulin to improve outcomes in survivors of AKI
🧐RMC-035 may improve kidney outcomes in settings characterized by oxidative and ischemia-reperfusion injury.
▶️ academic.oup.com/ndt/article-...
September 30, 2025 at 2:09 PM
Now online in @ndt-era.bsky.social
Recombinant alpha-1 microglobulin to improve outcomes in survivors of AKI
🧐RMC-035 may improve kidney outcomes in settings characterized by oxidative and ischemia-reperfusion injury.
▶️ academic.oup.com/ndt/article-...
Recombinant alpha-1 microglobulin to improve outcomes in survivors of AKI
🧐RMC-035 may improve kidney outcomes in settings characterized by oxidative and ischemia-reperfusion injury.
▶️ academic.oup.com/ndt/article-...
Reposted by Hans-Joachim Anders
October 14, 2025 at 11:06 AM
Now open access in @ndt-era.bsky.social
How can we target the production of pathogenic IgA in IgAN?
🧐Drugs directed at mucosal B cells, inhibitors of APRIL and BAFF, and drugs that target IgA-producing plasma cells
▶️https://academic.oup.com/ndt/article/doi/10.1093/ndt/gfaf185/8262262
How can we target the production of pathogenic IgA in IgAN?
🧐Drugs directed at mucosal B cells, inhibitors of APRIL and BAFF, and drugs that target IgA-producing plasma cells
▶️https://academic.oup.com/ndt/article/doi/10.1093/ndt/gfaf185/8262262
October 8, 2025 at 9:56 AM
Now open access in @ndt-era.bsky.social
How can we target the production of pathogenic IgA in IgAN?
🧐Drugs directed at mucosal B cells, inhibitors of APRIL and BAFF, and drugs that target IgA-producing plasma cells
▶️https://academic.oup.com/ndt/article/doi/10.1093/ndt/gfaf185/8262262
How can we target the production of pathogenic IgA in IgAN?
🧐Drugs directed at mucosal B cells, inhibitors of APRIL and BAFF, and drugs that target IgA-producing plasma cells
▶️https://academic.oup.com/ndt/article/doi/10.1093/ndt/gfaf185/8262262
Now online in @ndt-era.bsky.social
Recombinant alpha-1 microglobulin to improve outcomes in survivors of AKI
🧐RMC-035 may improve kidney outcomes in settings characterized by oxidative and ischemia-reperfusion injury.
▶️ academic.oup.com/ndt/article-...
Recombinant alpha-1 microglobulin to improve outcomes in survivors of AKI
🧐RMC-035 may improve kidney outcomes in settings characterized by oxidative and ischemia-reperfusion injury.
▶️ academic.oup.com/ndt/article-...
September 30, 2025 at 2:09 PM
Now online in @ndt-era.bsky.social
Recombinant alpha-1 microglobulin to improve outcomes in survivors of AKI
🧐RMC-035 may improve kidney outcomes in settings characterized by oxidative and ischemia-reperfusion injury.
▶️ academic.oup.com/ndt/article-...
Recombinant alpha-1 microglobulin to improve outcomes in survivors of AKI
🧐RMC-035 may improve kidney outcomes in settings characterized by oxidative and ischemia-reperfusion injury.
▶️ academic.oup.com/ndt/article-...
Now open access in @ndt-era.bsky.social
Prevalence of Strongyloides stercoralis in HD pts in Vienna
🧐Implementation of targeted screening for S. stercoralis should be considered in pre-KTX protocols in Europe.
▶️ academic.oup.com/ndt/article/...
Prevalence of Strongyloides stercoralis in HD pts in Vienna
🧐Implementation of targeted screening for S. stercoralis should be considered in pre-KTX protocols in Europe.
▶️ academic.oup.com/ndt/article/...
September 28, 2025 at 8:52 AM
Now open access in @ndt-era.bsky.social
Prevalence of Strongyloides stercoralis in HD pts in Vienna
🧐Implementation of targeted screening for S. stercoralis should be considered in pre-KTX protocols in Europe.
▶️ academic.oup.com/ndt/article/...
Prevalence of Strongyloides stercoralis in HD pts in Vienna
🧐Implementation of targeted screening for S. stercoralis should be considered in pre-KTX protocols in Europe.
▶️ academic.oup.com/ndt/article/...
Now open access in @ndt-era.bsky.social
QT-Prolonging Medications: Prevalence of Use and Associated Risks in CKD
🧐The pathophysiological relevance, prevalence, and CV consequences of QT-prolonging drug use in the CKD setting
▶️https://academic.oup.com/ndt/article/doi/10.1093/ndt/gfaf196/8263915
QT-Prolonging Medications: Prevalence of Use and Associated Risks in CKD
🧐The pathophysiological relevance, prevalence, and CV consequences of QT-prolonging drug use in the CKD setting
▶️https://academic.oup.com/ndt/article/doi/10.1093/ndt/gfaf196/8263915
September 27, 2025 at 9:14 PM
Now open access in @ndt-era.bsky.social
QT-Prolonging Medications: Prevalence of Use and Associated Risks in CKD
🧐The pathophysiological relevance, prevalence, and CV consequences of QT-prolonging drug use in the CKD setting
▶️https://academic.oup.com/ndt/article/doi/10.1093/ndt/gfaf196/8263915
QT-Prolonging Medications: Prevalence of Use and Associated Risks in CKD
🧐The pathophysiological relevance, prevalence, and CV consequences of QT-prolonging drug use in the CKD setting
▶️https://academic.oup.com/ndt/article/doi/10.1093/ndt/gfaf196/8263915
Now open access in @NDTsocial
Anti-GBM disease - Treatment Standard
🧐 Anti-GBM and ANCA positive pts have a higher relapse risk and require maintenance immunosuppressive treatment
▶️ academic.oup.com/ndt/article/...
Anti-GBM disease - Treatment Standard
🧐 Anti-GBM and ANCA positive pts have a higher relapse risk and require maintenance immunosuppressive treatment
▶️ academic.oup.com/ndt/article/...
September 18, 2025 at 8:15 PM
Now open access in @NDTsocial
Anti-GBM disease - Treatment Standard
🧐 Anti-GBM and ANCA positive pts have a higher relapse risk and require maintenance immunosuppressive treatment
▶️ academic.oup.com/ndt/article/...
Anti-GBM disease - Treatment Standard
🧐 Anti-GBM and ANCA positive pts have a higher relapse risk and require maintenance immunosuppressive treatment
▶️ academic.oup.com/ndt/article/...
Now open access in @ndt-era.bsky.social
Comparing CKD populations with T1D and T2D based on FINE-ONE and FIDELITY populations
🧐Similarities between populations may inform the translation of clinical evidence on finerenone from CKD and T2D to CKD and T1D.
▶️ academic.oup.com/ndt/article/...
Comparing CKD populations with T1D and T2D based on FINE-ONE and FIDELITY populations
🧐Similarities between populations may inform the translation of clinical evidence on finerenone from CKD and T2D to CKD and T1D.
▶️ academic.oup.com/ndt/article/...
September 16, 2025 at 10:55 AM
Now open access in @ndt-era.bsky.social
Comparing CKD populations with T1D and T2D based on FINE-ONE and FIDELITY populations
🧐Similarities between populations may inform the translation of clinical evidence on finerenone from CKD and T2D to CKD and T1D.
▶️ academic.oup.com/ndt/article/...
Comparing CKD populations with T1D and T2D based on FINE-ONE and FIDELITY populations
🧐Similarities between populations may inform the translation of clinical evidence on finerenone from CKD and T2D to CKD and T1D.
▶️ academic.oup.com/ndt/article/...
Now open access in @ndt-era.bsky.social al
CKD of unexplained cause (CKDx): A consensus statement by the Genes &Kidney Working Group of the ERA
🧐Check also our 2 open access editorials on this innovative concept.
▶️ academic.oup.com/ndt/article/...
CKD of unexplained cause (CKDx): A consensus statement by the Genes &Kidney Working Group of the ERA
🧐Check also our 2 open access editorials on this innovative concept.
▶️ academic.oup.com/ndt/article/...
September 14, 2025 at 8:28 AM
Now open access in @ndt-era.bsky.social al
CKD of unexplained cause (CKDx): A consensus statement by the Genes &Kidney Working Group of the ERA
🧐Check also our 2 open access editorials on this innovative concept.
▶️ academic.oup.com/ndt/article/...
CKD of unexplained cause (CKDx): A consensus statement by the Genes &Kidney Working Group of the ERA
🧐Check also our 2 open access editorials on this innovative concept.
▶️ academic.oup.com/ndt/article/...
Now online in @ndt-era.bsky.social
Transition of pts with hereditary nephropathies from pediatric to adult care
from WG Genes&Kidney of ERA and ESPN
🧐To improve health outcomes, pt empowerment, and engagement for young people with CKD.
▶️ academic.oup.com/ndt/article-...
Transition of pts with hereditary nephropathies from pediatric to adult care
from WG Genes&Kidney of ERA and ESPN
🧐To improve health outcomes, pt empowerment, and engagement for young people with CKD.
▶️ academic.oup.com/ndt/article-...
September 12, 2025 at 7:42 AM
Now online in @ndt-era.bsky.social
Transition of pts with hereditary nephropathies from pediatric to adult care
from WG Genes&Kidney of ERA and ESPN
🧐To improve health outcomes, pt empowerment, and engagement for young people with CKD.
▶️ academic.oup.com/ndt/article-...
Transition of pts with hereditary nephropathies from pediatric to adult care
from WG Genes&Kidney of ERA and ESPN
🧐To improve health outcomes, pt empowerment, and engagement for young people with CKD.
▶️ academic.oup.com/ndt/article-...
New RCT online in @ndt-era.bsky.social
Additive Effects of Oral Calcitriol on pts with IgAN receiving RAS Blockade
🧐The addition of 0.25 μg/d calcitriol to RASi safely lowered residual proteinuria and slowed eGFR decline in pts with IgAN
▶️ academic.oup.com/ndt/article-...
Additive Effects of Oral Calcitriol on pts with IgAN receiving RAS Blockade
🧐The addition of 0.25 μg/d calcitriol to RASi safely lowered residual proteinuria and slowed eGFR decline in pts with IgAN
▶️ academic.oup.com/ndt/article-...
September 12, 2025 at 7:29 AM
New RCT online in @ndt-era.bsky.social
Additive Effects of Oral Calcitriol on pts with IgAN receiving RAS Blockade
🧐The addition of 0.25 μg/d calcitriol to RASi safely lowered residual proteinuria and slowed eGFR decline in pts with IgAN
▶️ academic.oup.com/ndt/article-...
Additive Effects of Oral Calcitriol on pts with IgAN receiving RAS Blockade
🧐The addition of 0.25 μg/d calcitriol to RASi safely lowered residual proteinuria and slowed eGFR decline in pts with IgAN
▶️ academic.oup.com/ndt/article-...
Now open access in @ndt-era.bsky.social
Protein profiles and associated biological pathways among different etiologies of CKD: new insights from DAPA-CKD
🧐Distinct proteomic differences unravel the heterogeneous pathophysiology of human CKD.
▶️ academic.oup.com/ndt/article/...
Protein profiles and associated biological pathways among different etiologies of CKD: new insights from DAPA-CKD
🧐Distinct proteomic differences unravel the heterogeneous pathophysiology of human CKD.
▶️ academic.oup.com/ndt/article/...
September 8, 2025 at 7:42 PM
Now open access in @ndt-era.bsky.social
Protein profiles and associated biological pathways among different etiologies of CKD: new insights from DAPA-CKD
🧐Distinct proteomic differences unravel the heterogeneous pathophysiology of human CKD.
▶️ academic.oup.com/ndt/article/...
Protein profiles and associated biological pathways among different etiologies of CKD: new insights from DAPA-CKD
🧐Distinct proteomic differences unravel the heterogeneous pathophysiology of human CKD.
▶️ academic.oup.com/ndt/article/...
Reposted by Hans-Joachim Anders
Which agent are you using in post kidney transplant dyslipidemia? statin, ezetimibe, PCSK9 modulators or bempedoic acid?
More info: academic.oup.com/ndt/article/...
@ndt-era.bsky.social, @hjanders.bsky.social
More info: academic.oup.com/ndt/article/...
@ndt-era.bsky.social, @hjanders.bsky.social
Lipid-lowering agents in solid organ transplant recipients
ABSTRACT. Although pre- and post-transplant dyslipidaemia is one of the most prevalent modifiable risk factors associated with an increased risk of major c
academic.oup.com
September 5, 2025 at 12:08 PM
Which agent are you using in post kidney transplant dyslipidemia? statin, ezetimibe, PCSK9 modulators or bempedoic acid?
More info: academic.oup.com/ndt/article/...
@ndt-era.bsky.social, @hjanders.bsky.social
More info: academic.oup.com/ndt/article/...
@ndt-era.bsky.social, @hjanders.bsky.social
Reposted by Hans-Joachim Anders
Acute kidney injury, acute kidney disease and chronic kidney disease: challenges and research perspectives
More info: academic.oup.com/ndt/article/...
@ndt-era.bsky.social, @hjanders.bsky.social
More info: academic.oup.com/ndt/article/...
@ndt-era.bsky.social, @hjanders.bsky.social
September 4, 2025 at 7:10 PM
Acute kidney injury, acute kidney disease and chronic kidney disease: challenges and research perspectives
More info: academic.oup.com/ndt/article/...
@ndt-era.bsky.social, @hjanders.bsky.social
More info: academic.oup.com/ndt/article/...
@ndt-era.bsky.social, @hjanders.bsky.social
Reposted by Hans-Joachim Anders
A step toward personalized medicine
More info: academic.oup.com/ndt/article/...
@ndt-era.bsky.social, @hjanders.bsky.social, @Richard Glassock, @Andrew Rule, @Aleksandar Denic, @delanaye.bsky.social
More info: academic.oup.com/ndt/article/...
@ndt-era.bsky.social, @hjanders.bsky.social, @Richard Glassock, @Andrew Rule, @Aleksandar Denic, @delanaye.bsky.social
September 3, 2025 at 10:20 PM
A step toward personalized medicine
More info: academic.oup.com/ndt/article/...
@ndt-era.bsky.social, @hjanders.bsky.social, @Richard Glassock, @Andrew Rule, @Aleksandar Denic, @delanaye.bsky.social
More info: academic.oup.com/ndt/article/...
@ndt-era.bsky.social, @hjanders.bsky.social, @Richard Glassock, @Andrew Rule, @Aleksandar Denic, @delanaye.bsky.social
Now online in @ndt-era.bsky.social
Cost-effectiveness of protein restricted diets in advanced CKD
🧐In pts adherent to diet prescription, low-protein diets delay the start of dialysis, improve survival, and save money
▶️ academic.oup.com/ndt/article-...
Cost-effectiveness of protein restricted diets in advanced CKD
🧐In pts adherent to diet prescription, low-protein diets delay the start of dialysis, improve survival, and save money
▶️ academic.oup.com/ndt/article-...
Cost-effectiveness of protein restricted diets in advanced CKD
AbstractBackground. The dialysis costs are not sustainable everywhere, resulting in many avoidable deaths. Interventions that postpone the start of dialysi
academic.oup.com
August 16, 2025 at 10:39 AM
Now online in @ndt-era.bsky.social
Cost-effectiveness of protein restricted diets in advanced CKD
🧐In pts adherent to diet prescription, low-protein diets delay the start of dialysis, improve survival, and save money
▶️ academic.oup.com/ndt/article-...
Cost-effectiveness of protein restricted diets in advanced CKD
🧐In pts adherent to diet prescription, low-protein diets delay the start of dialysis, improve survival, and save money
▶️ academic.oup.com/ndt/article-...
Now open access in @ndt-era.bsky.social
Anti-nephrin, anti-podocin and anti-Kirrel1 antibodies: Biological challenges and clinical implications
🧐 Clinical implementation of anti-slit diaphragm antibody testing = precision dx and tx in podocytopathies
▶️ academic.oup.com/ndt/article/...
Anti-nephrin, anti-podocin and anti-Kirrel1 antibodies: Biological challenges and clinical implications
🧐 Clinical implementation of anti-slit diaphragm antibody testing = precision dx and tx in podocytopathies
▶️ academic.oup.com/ndt/article/...
August 16, 2025 at 6:59 AM
Now open access in @ndt-era.bsky.social
Anti-nephrin, anti-podocin and anti-Kirrel1 antibodies: Biological challenges and clinical implications
🧐 Clinical implementation of anti-slit diaphragm antibody testing = precision dx and tx in podocytopathies
▶️ academic.oup.com/ndt/article/...
Anti-nephrin, anti-podocin and anti-Kirrel1 antibodies: Biological challenges and clinical implications
🧐 Clinical implementation of anti-slit diaphragm antibody testing = precision dx and tx in podocytopathies
▶️ academic.oup.com/ndt/article/...
Now open access in @ndt-era.bsky.social
What do RCTs teach us about the pathophysiology of human IgAN?
🧐B cells/PC produce the IgAN antigen GdIgA1 as well as the respective autoantibodies, hence targeting B cells/PC will be most clever.
▶️ academic.oup.com/ndt/article/...
What do RCTs teach us about the pathophysiology of human IgAN?
🧐B cells/PC produce the IgAN antigen GdIgA1 as well as the respective autoantibodies, hence targeting B cells/PC will be most clever.
▶️ academic.oup.com/ndt/article/...
August 13, 2025 at 8:16 AM
Now open access in @ndt-era.bsky.social
What do RCTs teach us about the pathophysiology of human IgAN?
🧐B cells/PC produce the IgAN antigen GdIgA1 as well as the respective autoantibodies, hence targeting B cells/PC will be most clever.
▶️ academic.oup.com/ndt/article/...
What do RCTs teach us about the pathophysiology of human IgAN?
🧐B cells/PC produce the IgAN antigen GdIgA1 as well as the respective autoantibodies, hence targeting B cells/PC will be most clever.
▶️ academic.oup.com/ndt/article/...
Now online in @ndt-era.bsky.social
Perlecan is a novel target of autoantibodies in anti-glomerular basement membrane disease
🧐Triple-positive pts (anti-type IV collagen, -laminin 521, and -perlecan) = highest prevalence of lung hemorrhage and ESKD
▶️ academic.oup.com/ndt/article-...
Perlecan is a novel target of autoantibodies in anti-glomerular basement membrane disease
🧐Triple-positive pts (anti-type IV collagen, -laminin 521, and -perlecan) = highest prevalence of lung hemorrhage and ESKD
▶️ academic.oup.com/ndt/article-...
August 12, 2025 at 5:27 AM
Now online in @ndt-era.bsky.social
Perlecan is a novel target of autoantibodies in anti-glomerular basement membrane disease
🧐Triple-positive pts (anti-type IV collagen, -laminin 521, and -perlecan) = highest prevalence of lung hemorrhage and ESKD
▶️ academic.oup.com/ndt/article-...
Perlecan is a novel target of autoantibodies in anti-glomerular basement membrane disease
🧐Triple-positive pts (anti-type IV collagen, -laminin 521, and -perlecan) = highest prevalence of lung hemorrhage and ESKD
▶️ academic.oup.com/ndt/article-...
Now open access in @ndt-era.bsky.social
Evolving strategies for early diagnosis, proactive prevention and treatment of CKD
🧐"Inferior doctors provide KRT
Mediocre doctors treat CKD
Superior doctors prevent kidney disease"
▶️
academic.oup.com/ndt/article/...
Evolving strategies for early diagnosis, proactive prevention and treatment of CKD
🧐"Inferior doctors provide KRT
Mediocre doctors treat CKD
Superior doctors prevent kidney disease"
▶️
academic.oup.com/ndt/article/...
August 11, 2025 at 9:08 AM
Now open access in @ndt-era.bsky.social
Evolving strategies for early diagnosis, proactive prevention and treatment of CKD
🧐"Inferior doctors provide KRT
Mediocre doctors treat CKD
Superior doctors prevent kidney disease"
▶️
academic.oup.com/ndt/article/...
Evolving strategies for early diagnosis, proactive prevention and treatment of CKD
🧐"Inferior doctors provide KRT
Mediocre doctors treat CKD
Superior doctors prevent kidney disease"
▶️
academic.oup.com/ndt/article/...
Reposted by Hans-Joachim Anders
Read this piece from the ERAKI working group at the @ndt-era.bsky.social regarding the results of the DEFENDER trial published last August @jama.com
academic.oup.com/ndt/article/...
academic.oup.com/ndt/article/...
July 13, 2025 at 11:20 PM
Read this piece from the ERAKI working group at the @ndt-era.bsky.social regarding the results of the DEFENDER trial published last August @jama.com
academic.oup.com/ndt/article/...
academic.oup.com/ndt/article/...